MITIGATE Trial Shows Uplizna Significantly Lowers Flare Risk, Glucocorticoid Dependence in IgG4-Related Disease
The Phase III MITIGATE trial demonstrated that Uplizna (inebilizumab) significantly reduces the risk of flares, lowers glucocorticoid dependence, and increases rates of treatment- and glucocorticoid-free remission in patients with immunoglobulin G4-related disease.
Credit: Naeblys | stock.adobe.com
Findings from the Phase III MITIGATE trial (NCT04540497) show the efficacy of Uplizna (inebilizumab) in lowering the risk of flares and reducing glucocorticoid dependence with higher rates of treatment- and glucocorticoid-free remission in patients with immunoglobulin G4-related disease (IgG4-RD).1,2 Uplizna is a humanized, afucosylated IgG1 kappa monoclonal antibody that was designed to target CD19 to induce rapid, deep, and durable B-cell depletion. The medication is currently indicated to treat neuromyelitis optica spectrum disorder in adults who are anti-aquaporin-4 antibody positive. IgG4-RD is a chronic, systemic, immune-mediated, fibroinflammatory condition that can potentially impact multiple organs.
“B-cell–targeted treatments offer potential benefits in the treatment of IgG4-related disease, but supporting data are derived exclusively from case reports and open-label studies. In an open-label study involving 30 patients, rituximab, a CD20-targeted, B-cell–depleting agent, appeared to induce remission, but data from randomized, controlled trials of rituximab for the treatment of persons with IgG4-related disease are lacking,” the study authors wrote. “CD19 expression appears earlier than CD20 expression in B-cell development and persists later, notably on plasmablasts and some plasma cells. Therefore, therapies targeting CD19 may be effective in the treatment of IgG4-related disease and may offer advantages over anti-CD20 strategies by means of targeting broader ranges of B cells that drive IgG4-related disease.”1
Trial Design
The randomized, double-blind, placebo-controlled, parallel-group, multicenter MITIGATE trial compared the efficacy and safety of Uplizna vs. placebo in lowering the risk of flares in adult patients with IgG4-RD. Investigators enrolled 135 patients with IgG4-RD who met the vast eligibility criteria, which included multi-organ disease history and active disease that was treated by glucocorticoids at the time of screening. This allowed for a patient population with a risk of flares to better assess the primary endpoint of time to first treated and adjudicated IgG4-RD flare, according to the investigators.
Patients enrolled in the trial were screened for up to 28 days, at which point they were randomly assigned in a 1:1 ratio to receive either 300 mg of intravenous Uplizna (n = 68) or placebo (n = 67) on days one and 15, and week 26 after premedication, and then followed for the subsequent 52-week randomized control period.
The trial’s key secondary endpoints included annualized flare rate, flare-free and treatment-free complete remission, and flare-free and corticosteroid-free complete remission. An optional three-year open-label treatment period and a safety follow-up period following discontinuation of Uplizna will run for up to two years as part of the trial. Results show that patients administered Uplizna experienced a reduction in flare risk, with 10% having at least one flare compared to 60% in the placebo cohort (hazard ratio, 0.13; 95% confidence interval [CI], 0.06 to 0.28; P<0.001).
The annualized flare rate was also lower among patients administered Uplizna compared to the placebo cohort (rate ratio, 0.14; 95% CI, 0.06 to 0.31; P<0.001). Further, a greater number of patients in the Uplizna cohort had flare-free and treatment-free complete remission compared to placebo (odds ratio, 4.68; 95% CI, 2.21 to 9.91; P<0.001), as well as flare-free, glucocorticoid-free complete remission compared to placebo (odds ratio, 4.96; 95% CI, 2.34 to 10.52; P<0.001).
In terms of safety, rates of adverse events (AEs) were similar among both cohorts; however, more AEs of grade 3 or higher, serious AEs, AEs of special interest, and AEs causing treatment discontinuation occurred in the Uplizna cohort. Serious AEs were reported by 18% of patients in the Uplizna cohort compared to 9% of patients in the placebo cohort.
“The MITIGATE trial showed the efficacy of CD19-targeted B-cell depletion by inebilizumab for the treatment of IgG4-related disease,” the study authors concluded. “Inebilizumab reduced the risk of disease flares and the annualized flare rate relative to placebo over the 52-week treatment period. More participants who received inebilizumab had treatment-free and glucocorticoid-free complete remission than did participants who received placebo. Participants who received inebilizumab required lower cumulative glucocorticoid exposure to induce remission and maintain disease control during the treatment period than participants who received placebo.”1
References
1. Stone J., et al. Inebilizumab for Treatment of IgG4-Related Disease. N Engl J Med 2025;392:1168-1177. DOI: 10.1056/NEJMoa2409712. Vol. 392 No. 12.
2. A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease. ClinicalTrials.gov. Updated November 5, 2024. Accessed March 28, 2025. https://clinicaltrials.gov/study/NCT04540497
FOCUS Trial Results Show Solriamfetol Significantly Reduces ADHD Symptoms, Severity in Adults
March 27th 2025Solriamfetol achieved the primary and key secondary endpoint of the Phase III FOCUS trial by significantly lowering attention-deficit hyperactivity disorder symptoms and disease severity in adults compared to placebo, with a favorable safety and tolerability profile.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
